entertainment -WSS

entertainment

author：knowledge 2025-10-01 18:45:19 - browse：28

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

entertainment

WSS

Explaining an after

All of Us, NIH's precision medicine initiative, gets a big boost

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Devoted Health’s losses in Medicare Advantage persist

Surgery pushed Ben Carson to fame

Why CTE doesn’t keep Americans from enjoying the Super Bowl

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Supreme Court strikes down use of affirmative action

Problems with a popular proposal to regulate AI in health care

Trump demands the U.S. pay no more for drugs than other countries … again

AstraZeneca stays mum on Medicare drug pricing negotiations

Anesthesiologist group: stop taking Ozempic before surgery

The CDC's new social media misinformation war

23andMe had bad news about my health. I wish a person had delivered it

Gene therapy’s promise and the high cost of hope

Cancer drug shortages should be causing more outrage

Texas Medical Board asked to define abortion emergency exception

knowledge

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Travis Kelce and the trap of celebrity vaccine endorsements

What’s missing from the debate over nursing home staff minimums

Medicare Advantage plans can’t deny care with AI, CMS warns

Readout LOUD: Venture capital, Gilead, and more M&A

Updated Covid vaccine has 54% effectiveness, new study suggests

entertainment

entertainment

entertainment

focus